All Posts

Introduction Few terms get misapplied in biotech project management as reliably as "Agile." Teams use it to mean flexible. Leaders use it to mean fast. And in some corners of the industry, it has become a catch-all for any process that lacks structure. The problem is that in drug development, the wrong kind of flexibility can delay a program, compromise data integrity, or create regulatory exposure that takes years to resolve. Agile project management is a legitimate and powe

Introduction Science rarely cooperates with project plans. This is not a criticism of drug development — it is the nature of the work. Hypotheses are tested, data surprises, regulators weigh in, and the path forward shifts. But there is a significant difference between expected change in a scientific program and uncontrolled scope expansion that quietly consumes timelines, budgets, and organizational focus. In drug development, that distinction does not always get the atten

Introduction Drug development is one of the most capital-intensive, risk-laden undertakings in any industry. Deloitte's 2024 analysis estimated an average cost of $2.23 billion per approved drug (link) , and the attrition statistics behind that number are sobering (link) . The average likelihood of approval for a new Phase I drug currently sits at just 6.7% — an all-time low — with Phase II remaining the most treacherous hurdle, where only 28% of programs successfully advance

Introduction In biotech and pharma, the line between "project" and "operation" blurs constantly — and when it does, accountability breaks down, resources get misallocated, and timelines slip in ways that are difficult to diagnose until the structural root cause is identified. Drug development looks linear from the outside: IND filing, Phase I, Phase II, Phase III, NDA submission. But inside that pipeline, organizations are simultaneously running clinical monitoring activities

Introduction Most biotech and pharma project failures don't begin when timelines slip or budgets blow. They begin in the first planning meeting, when the wrong questions were asked — or no questions were asked at all. In an industry defined by high-stakes investments and unforgiving regulatory timelines, that distinction matters enormously. IQVIA's 2025 Global Trends in R&D report found that total program duration from Phase I start to regulatory approval now averages 9.3 yea

PMO structure in biotech organizations Introduction When a biotech or pharma company reaches the point of asking "do we need a PMO?" — the conversation almost immediately diverges into a second, harder question: "what kind?" The Project Management Office is not a monolithic construct. It can function as a central command for standards and governance, a distributed support system embedded within business units, or something deliberately in between. In life sciences, where orga

Introduction The instinct in project management is to celebrate when the project closes — deliverables handed off, resources released, final report filed. But in biotech and pharma, like most industries, the real question isn't "did we finish?" — it's "did it matter?". Projects are investments. Every project begins with a business case that outlines expected costs, benefits, and value creation — yet most organizations lack a post-closure framework to actually verify that valu

In biotech and pharmaceutical projects, managing complexity is a daily challenge. These projects often involve cutting-edge science, strict regulatory requirements, and multiple stakeholders. To navigate this landscape, project managers rely on structure to keep efforts focused and measurable. Yet, too much rigidity can stifle innovation and slow progress. Finding the right balance between structure and flexibility is essential for success. This post explores why structure ma

Project management is often seen as a set of processes, tools, and documentation aimed at delivering projects on time and within budget. Yet, the true measure of success lies in the value a project brings to an organization. Without a clear focus on value, projects risk wasting resources, losing direction, and ultimately failing to meet their intended goals. This post explores why every aspect of project management must be value-driven — from deciding whether to start a proje

Project success in the pharmaceutical and biotech industries depends on precise control of scope, schedule, and cost. Earned Value Management (EVM) offers a proven way to track these elements together, providing clear insights into project health. This post explains how EVM works, why it matters in pharma, and how to apply best practices aligned with PMI standards to improve project outcomes. Project manager analyzing schedule and cost data in pharmaceutical project What Is E

When biotech and pharma projects stall, go over budget, or collapse entirely, the root cause is rarely purely technical — it's almost always structural. One of the most consistent structural failures is a misalignment between authority and accountability: people are held accountable for outcomes they don't have the power to influence, or given power without the ownership that should come with it. This misalignment is especially consequential in life sciences, biotech, and pha